In a small study involving children with autism, those who were CYP2D6 poor metabolizers had higher drug concentration and exhibited adverse effects including hyperprolactinemia and tardive dyskinesia, while ultra-rapid metabolizers exhibited no adverse effect [47]; however, the differences in drug response were not statistically significant. The gene discussed is CYP2D6; the disease is hyperprolactinemia.